Linrodostat (development code BMS-986205) is an experimental drug being studied for its immunomodulating and antineoplastic activities.
Linrodostat is an inhibitor of indoleamine 2,3-dioxygenase 1 (IDO1).
Linrodostat has entered clinical trials for a variety of cancer types including bladder cancer, head and neck cancer, endometrial cancer, gastric cancer, melanoma, liver cancer, non-small cell lung cancer, and solid tumors.